Price
CHART BY
Frequently asked questions
What is Abeona's market capitalization?
The market capitalization of Abeona is €275.09M. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Abeona?
Abeona's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -€1.149. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Abeona's stock?
Currently, 6 analysts cover Abeona's stock, with a consensus target price of €17.12. Analyst ratings provide insights into the stock's expected performance.
What is the EBITDA for Abeona?
Abeona's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -€56.38M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Abeona?
Abeona has a free cash flow of -€54.12M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Abeona have, and what sector and industry does it belong to?
Abeona employs approximately 136 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Abeona's shares?
The free float of Abeona is 45.48M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- €275.09M
- EPS (TTM)
- -€1.149
- Free Float
- 45.48M
- EBITDA (TTM)
- -€56.38M
- Free Cashflow (TTM)
- -€54.12M
Pricing
- 1D span
- €5.25€5.475
- 52W span
- €3.538€6.465
Analyst Ratings
The price target is €17.12 and the stock is covered by 6 analysts.
Buy
6
Hold
0
Sell
0
Information
Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life-threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB), ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA), and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in Cleveland, OH.
- Employees
- 136
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- ISIN
- US00289Y2063
- Primary Ticker
- ABEO
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet